1
|
Baghbani F, Raoofian R, Hasanzadeh Nazarabadi M, Hamzehloei T, Soukhtanloo M, Heidari M, Afsharzadeh SM, Shekouhi S, Moradi F, Sarli AA, Zavar-Reza J, Mojarrad M. Identification of novel hypoxia response genes in human glioma cell line a172. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES 2013; 16:675-82. [PMID: 23826488 PMCID: PMC3700041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 10/10/2012] [Indexed: 12/02/2022]
Abstract
OBJECTIVE(S) Hypoxia is a serious challenge for treatment of solid tumors. This condition has been manifested to exert significant therapeutic effects on glioblastoma multiform or (WHO) astrocytoma grade IV. Hypoxia contributes numerous changes in cellular mechanisms such as angiogenesis, metastasis and apoptosis evasion. Furthermore, in molecular level, hypoxia can cause induction of DNA breaks in tumor cells. Identification of mechanisms responsible for these effects can lead to designing more efficient therapeutic strategies against tumor progression which results in improvement of patient prognosis. Materials and Methods : In order to identify more hypoxia regulated genes which may have a role in glioblastoma progression, cDNA-AFLP was optimized as a Differential display method which is able to identify and isolate transcripts with no prior sequence knowledge. RESULTS Using this method, the current study identified 120 Transcription Derived Fragments (TDFs) which were completely differentially regulated in response to hypoxia. By sequence homology searching, the current study could detect 22 completely differentially regulated known genes and two unknown sequence matching with two chromosome contig and four sequence matches with some Expressed Sequence Tags (ESTs). CONCLUSION Further characterizing of these genes may help to achieve better understanding of hypoxia mediated phenotype change in tumor cells.
Collapse
Affiliation(s)
- Fatemeh Baghbani
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Reza Raoofian
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | | | - Tayebeh Hamzehloei
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohammad Soukhtanloo
- Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mansur Heidari
- Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Seyed Morteza Afsharzadeh
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Sahar Shekouhi
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Fahimeh Moradi
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Abdol-Azim Sarli
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Javad Zavar-Reza
- Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | - Majid Mojarrad
- Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran,Corresponding author: Majid Mojarrad, Ferdowsi Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: +98-511-8002243; +98-9158154330;
| |
Collapse
|